Mesenchymal stem cells from amniotic fluid for treating congenital and other diseases

Shaun M. Kunisaki

doi:10.1016/B978-0-12-801238-3.65512-5

Mesenchymal stem cells from amniotic fluid for treating congenital and other diseases

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Over the past decade, amniotic fluid-derived mesenchymal stem/stromal cells (AF-MSCs) have emerged as a novel, experimental approach for the treatment of a wide variety of congenital anomalies diagnosed either in utero or postnatally. This article gives a pediatric surgeon’s perspective on AF-MSC therapy for the management of congenital anomalies and other diseases. The current status in preterm AF-MSC research, particularly as it relates to tissue engineering-based applications, is described in various experimental animal models. A roadmap for further study and eventual clinical application is also proposed.

Original language	English (US)
Title of host publication	Encyclopedia of Tissue Engineering and Regenerative Medicine
Publisher	Elsevier
Pages	513-520
Number of pages	8
Volume	1-3
ISBN (Electronic)	9780128136997
ISBN (Print)	9780128137000
DOIs	https://doi.org/10.1016/B978-0-12-801238-3.65512-5
State	Published - Jan 1 2019
Externally published	Yes

Keywords

Amniocytes
Amniotic fluid
Congenital anomalies
Fetal therapy
Fetus
Induced pluripotent stem cells
Mesenchymal stem cells
Stem cell therapy
Stem cells
Tissue engineering

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1016/B978-0-12-801238-3.65512-5

Cite this

@inbook{2fc9fc2739424cfbb938f94e006cc60d,

title = "Mesenchymal stem cells from amniotic fluid for treating congenital and other diseases",

abstract = "Over the past decade, amniotic fluid-derived mesenchymal stem/stromal cells (AF-MSCs) have emerged as a novel, experimental approach for the treatment of a wide variety of congenital anomalies diagnosed either in utero or postnatally. This article gives a pediatric surgeon{\textquoteright}s perspective on AF-MSC therapy for the management of congenital anomalies and other diseases. The current status in preterm AF-MSC research, particularly as it relates to tissue engineering-based applications, is described in various experimental animal models. A roadmap for further study and eventual clinical application is also proposed.",

keywords = "Amniocytes, Amniotic fluid, Congenital anomalies, Fetal therapy, Fetus, Induced pluripotent stem cells, Mesenchymal stem cells, Stem cell therapy, Stem cells, Tissue engineering",

author = "Kunisaki, {Shaun M.}",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-801238-3.65512-5",

language = "English (US)",

isbn = "9780128137000",

volume = "1-3",

pages = "513--520",

booktitle = "Encyclopedia of Tissue Engineering and Regenerative Medicine",

publisher = "Elsevier",

}

TY - CHAP

T1 - Mesenchymal stem cells from amniotic fluid for treating congenital and other diseases

AU - Kunisaki, Shaun M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Over the past decade, amniotic fluid-derived mesenchymal stem/stromal cells (AF-MSCs) have emerged as a novel, experimental approach for the treatment of a wide variety of congenital anomalies diagnosed either in utero or postnatally. This article gives a pediatric surgeon’s perspective on AF-MSC therapy for the management of congenital anomalies and other diseases. The current status in preterm AF-MSC research, particularly as it relates to tissue engineering-based applications, is described in various experimental animal models. A roadmap for further study and eventual clinical application is also proposed.

AB - Over the past decade, amniotic fluid-derived mesenchymal stem/stromal cells (AF-MSCs) have emerged as a novel, experimental approach for the treatment of a wide variety of congenital anomalies diagnosed either in utero or postnatally. This article gives a pediatric surgeon’s perspective on AF-MSC therapy for the management of congenital anomalies and other diseases. The current status in preterm AF-MSC research, particularly as it relates to tissue engineering-based applications, is described in various experimental animal models. A roadmap for further study and eventual clinical application is also proposed.

KW - Amniocytes

KW - Amniotic fluid

KW - Congenital anomalies

KW - Fetal therapy

KW - Fetus

KW - Induced pluripotent stem cells

KW - Mesenchymal stem cells

KW - Stem cell therapy

KW - Stem cells

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=85078652254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078652254&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801238-3.65512-5

DO - 10.1016/B978-0-12-801238-3.65512-5

M3 - Chapter

AN - SCOPUS:85078652254

SN - 9780128137000

VL - 1-3

SP - 513

EP - 520

BT - Encyclopedia of Tissue Engineering and Regenerative Medicine

PB - Elsevier

ER -

Mesenchymal stem cells from amniotic fluid for treating congenital and other diseases

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this